Is RENATA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RENATA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RENATA (BDT640.1) is trading above our estimate of fair value (BDT119.54)
Significantly Below Fair Value: RENATA is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RENATA?
Key metric: As RENATA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for RENATA. This is calculated by dividing RENATA's market cap by their current
earnings.
What is RENATA's PE Ratio?
PE Ratio
20.3x
Earnings
৳3.62b
Market Cap
৳73.42b
RENATA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: RENATA is good value based on its Price-To-Earnings Ratio (20.3x) compared to the Asian Pharmaceuticals industry average (24.7x).
Price to Earnings Ratio vs Fair Ratio
What is RENATA's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
RENATA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
20.3x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RENATA's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.